CA3245962A1 - COMBINATIONS INCLUDING METAP2 INHIBITORS FOR CANCER TREATMENT - Google Patents
COMBINATIONS INCLUDING METAP2 INHIBITORS FOR CANCER TREATMENTInfo
- Publication number
- CA3245962A1 CA3245962A1 CA3245962A CA3245962A CA3245962A1 CA 3245962 A1 CA3245962 A1 CA 3245962A1 CA 3245962 A CA3245962 A CA 3245962A CA 3245962 A CA3245962 A CA 3245962A CA 3245962 A1 CA3245962 A1 CA 3245962A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- subject
- administered
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263320347P | 2022-03-16 | 2022-03-16 | |
| US63/320,347 | 2022-03-16 | ||
| US202263340726P | 2022-05-11 | 2022-05-11 | |
| US63/340,726 | 2022-05-11 | ||
| PCT/US2023/064550 WO2023178255A1 (en) | 2022-03-16 | 2023-03-16 | Combinations comprising metap2 inhibitors for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3245962A1 true CA3245962A1 (en) | 2023-09-21 |
Family
ID=85979451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3245962A Pending CA3245962A1 (en) | 2022-03-16 | 2023-03-16 | COMBINATIONS INCLUDING METAP2 INHIBITORS FOR CANCER TREATMENT |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20260014194A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4493181A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025509613A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240164549A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119300818A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023235307A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3245962A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024011197A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023178255A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021378944A1 (en) * | 2020-11-11 | 2023-06-15 | Syndevrx, Inc. | Combinations of metap2 inhibitors and cdk4/6 inhibitors for the treatment of cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3177603T3 (en) * | 2014-08-04 | 2019-01-14 | Merck Patent Gmbh | PYRROLIDINE UNDERIVATIVES AS METAP-2 INHIBITORS |
| US11612577B2 (en) * | 2018-10-26 | 2023-03-28 | Syndevrx, Inc. | Biomarkers of METAP2 inhibitors and applications thereof |
-
2023
- 2023-03-16 WO PCT/US2023/064550 patent/WO2023178255A1/en not_active Ceased
- 2023-03-16 KR KR1020247034327A patent/KR20240164549A/ko active Pending
- 2023-03-16 EP EP23716148.4A patent/EP4493181A1/en active Pending
- 2023-03-16 CN CN202380040935.XA patent/CN119300818A/zh active Pending
- 2023-03-16 MX MX2024011197A patent/MX2024011197A/es unknown
- 2023-03-16 CA CA3245962A patent/CA3245962A1/en active Pending
- 2023-03-16 AU AU2023235307A patent/AU2023235307A1/en active Pending
- 2023-03-16 US US18/846,365 patent/US20260014194A1/en active Pending
- 2023-03-16 JP JP2024554864A patent/JP2025509613A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023178255A9 (en) | 2024-09-26 |
| EP4493181A1 (en) | 2025-01-22 |
| AU2023235307A1 (en) | 2024-10-17 |
| KR20240164549A (ko) | 2024-11-19 |
| MX2024011197A (es) | 2024-09-18 |
| JP2025509613A (ja) | 2025-04-11 |
| CN119300818A (zh) | 2025-01-10 |
| WO2023178255A1 (en) | 2023-09-21 |
| US20260014194A1 (en) | 2026-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7019422B2 (ja) | 癌を治療するための方法 | |
| TWI680760B (zh) | 治療黑色素瘤的藥物組合 | |
| EP4385571B1 (en) | A lysyl oxidase-like 2 inhibitor for use in treating primary myelofibrosis | |
| JP2025032212A (ja) | ＭｅｔＡＰ２阻害剤のバイオマーカーとその応用 | |
| KR20250089532A (ko) | 암 치료를 위한 serd의 조합 | |
| TW202332431A (zh) | 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 | |
| JP2021505571A (ja) | 末梢ｔ細胞リンパ腫および皮膚ｔ細胞リンパ腫を治療するための組成物および方法 | |
| CN111757731A (zh) | 三取代苯并三唑衍生物的使用方法 | |
| JP2023501912A (ja) | 急性骨髄性白血病の治療のためのｄｈｏｄｈ阻害剤を含む組成物 | |
| AU2018234903B2 (en) | Combination therapies for the treatment of breast cancer | |
| JP2024502671A (ja) | ピリド［１，２－ａ］ピリミジノン類似体の使用 | |
| US11389536B2 (en) | Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent | |
| JP2016520662A (ja) | Ｐｉ３ｋ阻害剤および微小管不安定化剤の医薬組み合わせ | |
| US20260014194A1 (en) | Combinations comprising metap2 inhibitors for the treatment of cancer | |
| ES3030540T3 (en) | Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077 | |
| EP4203963B1 (en) | Combination therapy of naporafenib and trametinib for use in the treatment of sarcoma | |
| CN114599363A (zh) | Cxcr7拮抗剂与s1p1受体调节剂的组合 | |
| KR20160101027A (ko) | 제약 조합물 | |
| JP2023030112A (ja) | 肥満細胞疾患の処置のための方法及び医薬組成物 | |
| US20060258692A1 (en) | Quinazolinone compositions for regulation of gene expression related to pathological processes | |
| US20250241923A1 (en) | A dual selective pi3k delta and gamma inhibitors and/or a salt-inducible kinase 3 inhibitor for treating solid tumors | |
| JP4522261B2 (ja) | ブドウ膜黒色腫の処置 | |
| EP4719405A1 (en) | Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer | |
| AU2024304092A1 (en) | Use of akt inhibitor in preparation of drug for preventing or treating breast cancer | |
| CN116327772A (zh) | SMO抑制剂Sonidegib对管腔型乳腺癌骨转移的靶向治疗方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240913 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241008 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241008 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241008 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250213 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250307 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250307 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250307 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260306 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260306 |